NO793759L - Vandig blanding. - Google Patents

Vandig blanding.

Info

Publication number: NO793759L
Authority: NO; Norway
Prior art keywords: lecithin; water; dihexanoyl; pharmaceutical active; approx
Prior art date: 1978-11-21

Application number

NO793759A

Other languages

English (en)

Norwegian (no)

Inventor

Dieter Schmidt

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-11-21

Filing date

1979-11-20

Publication date

1980-05-22

1979-11-20 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1980-05-22 Publication of NO793759L publication Critical patent/NO793759L/no

Links

238000002156 mixing Methods 0.000 title claims description 3
239000000203 mixture Substances 0.000 claims description 34
DVZARZBAWHITHR-GOSISDBHSA-N 1,2-dihexanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCC(=O)OC[C@@H](OC(=O)CCCCC)COP([O-])(=O)OCC[N+](C)(C)C DVZARZBAWHITHR-GOSISDBHSA-N 0.000 claims description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
239000013543 active substance Substances 0.000 claims description 20
150000002632 lipids Chemical class 0.000 claims description 17
238000000034 method Methods 0.000 claims description 14
239000008344 egg yolk phospholipid Substances 0.000 claims description 11
229930003231 vitamin Natural products 0.000 claims description 11
235000013343 vitamin Nutrition 0.000 claims description 11
239000011782 vitamin Substances 0.000 claims description 11
229940088594 vitamin Drugs 0.000 claims description 11
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 9
239000008347 soybean phospholipid Substances 0.000 claims description 9
229960003529 diazepam Drugs 0.000 claims description 8
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 8
239000003960 organic solvent Substances 0.000 claims description 7
150000003722 vitamin derivatives Chemical class 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
229940049706 benzodiazepine Drugs 0.000 claims description 5
230000002949 hemolytic effect Effects 0.000 claims description 5
239000007853 buffer solution Substances 0.000 claims description 4
238000003756 stirring Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 claims description 2
QIJYAMAPPUXBSC-CQSZACIVSA-N PC(4:0/4:0) Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)COP([O-])(=O)OCC[N+](C)(C)C QIJYAMAPPUXBSC-CQSZACIVSA-N 0.000 claims description 2
238000010790 dilution Methods 0.000 claims description 2
239000012895 dilution Substances 0.000 claims description 2
CITHEXJVPOWHKC-UHFFFAOYSA-N dimyristoyl phosphatidylcholine Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UHFFFAOYSA-N 0.000 claims description 2
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
235000019155 vitamin A Nutrition 0.000 claims description 2
239000011719 vitamin A Substances 0.000 claims description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
229940045997 vitamin a Drugs 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
239000008055 phosphate buffer solution Substances 0.000 description 15
239000000243 solution Substances 0.000 description 11
238000001704 evaporation Methods 0.000 description 8
230000008020 evaporation Effects 0.000 description 7
239000000787 lecithin Substances 0.000 description 7
235000010445 lecithin Nutrition 0.000 description 7
239000000693 micelle Substances 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
150000001557 benzodiazepines Chemical class 0.000 description 3
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
230000003381 solubilizing effect Effects 0.000 description 3
229940042585 tocopherol acetate Drugs 0.000 description 3
235000019168 vitamin K Nutrition 0.000 description 3
239000011712 vitamin K Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229930003448 Vitamin K Natural products 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
150000003721 vitamin K derivatives Chemical class 0.000 description 2
229940046010 vitamin k Drugs 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
USPSDZQQNLMVMK-UHFFFAOYSA-N 1-Monolinolein Natural products CCCCCC=CC=CCCCCCCCC(=O)OCC(O)CO USPSDZQQNLMVMK-UHFFFAOYSA-N 0.000 description 1
WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229960002729 bromazepam Drugs 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000001989 choleretic effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
229960003120 clonazepam Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
-1 ethanol Chemical compound 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
229960002200 flunitrazepam Drugs 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
229960002225 medazepam Drugs 0.000 description 1
229940074096 monoolein Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000004289 sodium hydrogen sulphite Substances 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO793759A 1978-11-21 1979-11-20 Vandig blanding. NO793759L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH1192178		1978-11-21

Publications (1)

Publication Number	Publication Date
NO793759L true NO793759L (no)	1980-05-22

Family

ID=4378189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO793759A NO793759L (no)	1978-11-21	1979-11-20	Vandig blanding.

Country Status (22)

Country	Link
US (1)	US4271196A (es)
EP (1)	EP0011745B1 (es)
JP (1)	JPS5572111A (es)
KR (1)	KR850000584B1 (es)
AR (1)	AR225294A1 (es)
AT (1)	ATE501T1 (es)
AU (1)	AU529061B2 (es)
CA (1)	CA1136988A (es)
DE (1)	DE2961718D1 (es)
DK (1)	DK494079A (es)
ES (1)	ES8101855A1 (es)
FI (1)	FI793461A (es)
GR (1)	GR73668B (es)
HU (1)	HU180792B (es)
IE (1)	IE48659B1 (es)
IL (1)	IL58723A (es)
MC (1)	MC1297A1 (es)
NO (1)	NO793759L (es)
NZ (1)	NZ192118A (es)
PH (1)	PH15561A (es)
PT (1)	PT70478A (es)
ZA (1)	ZA796116B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2952115C2 (de) *	1979-12-22	1982-05-06	A. Nattermann & Cie GmbH, 5000 Köln	Rosmarinsäure-Phospholipid-Komplex
US4374082A (en) *	1981-08-18	1983-02-15	Richard Hochschild	Method for making a pharmaceutical and/or nutritional dosage form
US4457918A (en) *	1982-05-12	1984-07-03	The General Hospital Corporation	Glycosides of vitamins A, E and K
CA1237670A (en) *	1983-05-26	1988-06-07	Andrew S. Janoff	Drug preparations of reduced toxicity
US5059591B1 (en) *	1983-05-26	2000-04-25	Liposome Co Inc	Drug preparations of reduced toxicity
US4622219A (en) *	1983-06-17	1986-11-11	Haynes Duncan H	Method of inducing local anesthesia using microdroplets of a general anesthetic
JPS60208910A (ja) *	1984-03-31	1985-10-21	Green Cross Corp:The	水難溶性薬物・リン脂質複合体の製造方法
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
US4891208A (en) *	1985-04-10	1990-01-02	The Liposome Company, Inc.	Steroidal liposomes
US5231112A (en)	1984-04-12	1993-07-27	The Liposome Company, Inc.	Compositions containing tris salt of cholesterol hemisuccinate and antifungal
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US5023271A (en) *	1985-08-13	1991-06-11	California Biotechnology Inc.	Pharmaceutical microemulsions
US4861580A (en) *	1985-10-15	1989-08-29	The Liposome Company, Inc.	Composition using salt form of organic acid derivative of alpha-tocopheral
US5041278A (en) *	1985-10-15	1991-08-20	The Liposome Company, Inc.	Alpha tocopherol-based vesicles
CA1319886C (en) *	1987-02-03	1993-07-06	Alberto Ferro	Mixed micelle solutions
IT1269569B (it) *	1994-04-22	1997-04-08	Ugo Citernesi	Procedimento per la preparazione di complessi fra fosfolipidi e principi attivi utili per la produzione di liposomi e principi attivi e liposomi ottenuti con il procedimento
EP0682943B1 (de) *	1994-05-20	2003-08-20	GESELLSCHAFT FÜR MEDIZINISCHE FORSCHUNG UND WEITERBILDUNG e.V. GMF	Lormetazepamhaltige Öl-in-Wasser-Emulsion
JP2740153B2 (ja) *	1995-03-07	1998-04-15	エフ・ホフマン−ラロシユアーゲー	混合ミセル
WO1997014407A1 (en) *	1995-10-17	1997-04-24	Research Triangle Pharmaceuticals	Insoluble drug delivery
US7255877B2 (en) *	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
IL137734A0 (en) *	1998-02-11	2001-10-31	Res Triangle Pharm Ltd	Method and composition for treatment of inflammatory conditions
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
AU764001B2 (en)	1998-05-29	2003-08-07	Skyepharma Canada Inc.	Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
WO2000010531A1 (en)	1998-08-19	2000-03-02	Rtp Pharma Inc.	Injectable aqueous dispersions of propofol
RU2233654C2 (ru)	1998-11-20	2004-08-10	Ртп Фарма Инк.	Диспергируемые стабилизированные фосфолипидом микрочастицы
US6447806B1 (en)	1999-02-25	2002-09-10	Novartis Ag	Pharmaceutical compositions comprised of stabilized peptide particles
JP2003509453A (ja) *	1999-09-21	2003-03-11	アールティーピー・ファーマ・インコーポレーテッド	生物学的に活性な物質の、表面改質された粒状組成物
EP1276465B1 (en)	2000-04-20	2014-03-12	Jagotec AG	Improved water-insoluble drug particle process
AU8847101A (en)	2000-08-31	2002-03-13	Rtp Pharma Inc	Milled particles
TWI354568B (en) *	2000-09-20	2011-12-21	Jagotec Ag	Insoluble drug particle compositions with improved
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
ATE357216T1 (de) *	2001-02-22	2007-04-15	Jagotec Ag	Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
FR2833842B1 (fr) *	2001-12-21	2004-02-13	Aventis Pharma Sa	Compositions pharmaceutiques a base de derives d'azetidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU29060A1 (es) *
LU28584A1 (es) *
FR2102537A5 (es) *	1970-08-07	1972-04-07	Ugine Kuhlmann
FR2270887A1 (en) *	1974-05-16	1975-12-12	Chabrier De Lassauniere Pierre	Prepn of lecithins and glycol-lecithins - by reaction of trimethylamine with 2-substd-2-oxo-1,3,2-dioxaphospholans
SE442014B (sv) *	1976-10-12	1985-11-25	Barry D Sears	Syntetisk fosfatidyl-kvarter ammoniumforening till anvendning for solubilisering eller emulgering av vattenolosliga foreningar

1979
- 1979-01-24 GR GR60545A patent/GR73668B/el unknown
- 1979-10-03 CA CA000336919A patent/CA1136988A/en not_active Expired
- 1979-10-24 AR AR278611A patent/AR225294A1/es active
- 1979-11-05 FI FI793461A patent/FI793461A/fi not_active Application Discontinuation
- 1979-11-08 DE DE7979104378T patent/DE2961718D1/de not_active Expired
- 1979-11-08 EP EP79104378A patent/EP0011745B1/de not_active Expired
- 1979-11-08 AT AT79104378T patent/ATE501T1/de not_active IP Right Cessation
- 1979-11-12 PH PH23274A patent/PH15561A/en unknown
- 1979-11-14 AU AU52824/79A patent/AU529061B2/en not_active Ceased
- 1979-11-14 IL IL58723A patent/IL58723A/xx unknown
- 1979-11-14 ZA ZA00796116A patent/ZA796116B/xx unknown
- 1979-11-14 NZ NZ192118A patent/NZ192118A/xx unknown
- 1979-11-15 MC MC791415A patent/MC1297A1/xx unknown
- 1979-11-16 US US06/094,813 patent/US4271196A/en not_active Expired - Lifetime
- 1979-11-16 HU HU79HO2196A patent/HU180792B/hu unknown
- 1979-11-19 JP JP14903879A patent/JPS5572111A/ja active Granted
- 1979-11-20 DK DK494079A patent/DK494079A/da not_active Application Discontinuation
- 1979-11-20 KR KR7904064A patent/KR850000584B1/ko active
- 1979-11-20 IE IE2216/79A patent/IE48659B1/en unknown
- 1979-11-20 PT PT70478A patent/PT70478A/pt unknown
- 1979-11-20 ES ES486157A patent/ES8101855A1/es not_active Expired
- 1979-11-20 NO NO793759A patent/NO793759L/no unknown

Also Published As

Publication number	Publication date
JPS5572111A (en)	1980-05-30
US4271196A (en)	1981-06-02
NZ192118A (en)	1981-12-15
HU180792B (en)	1983-04-29
AU5282479A (en)	1980-05-29
EP0011745A1 (de)	1980-06-11
ES486157A0 (es)	1981-01-16
MC1297A1 (fr)	1980-10-03
AU529061B2 (en)	1983-05-26
ES8101855A1 (es)	1981-01-16
GR73668B (es)	1984-03-28
IL58723A (en)	1982-11-30
KR850000584B1 (ko)	1985-04-30
DK494079A (da)	1980-05-22
IL58723A0 (en)	1980-02-29
JPH0122243B2 (es)	1989-04-25
AR225294A1 (es)	1982-03-15
ZA796116B (en)	1980-11-26
PH15561A (en)	1983-02-11
PT70478A (en)	1979-12-01
CA1136988A (en)	1982-12-07
IE792216L (en)	1980-05-21
FI793461A (fi)	1980-05-22
DE2961718D1 (en)	1982-02-18
IE48659B1 (en)	1985-04-03
EP0011745B1 (de)	1981-12-30
ATE501T1 (de)	1982-01-15

Publication	Publication Date	Title
NO793759L (no)	1980-05-22	Vandig blanding.
DK149483B (da)	1986-06-30	Fremgangsmaade til fremstilling af vandbaserede injektionsoploesninger indeholdende galdesyrederivater, phosphatider og benzodiazepin
DK175662B1 (da)	2005-01-10	Blandingsmicelleoplösninger med ikke-steroide inflammationshæmmmere
EP1059941B1 (en)	2004-05-26	Pharmaceutical compositions and their use
EP1389089B1 (en)	2009-08-26	Method and composition for solubilising a biologically active compound with low water solubility
US4328222A (en)	1982-05-04	Pharmaceutical compositions for parenteral or local administration
DK165219B (da)	1992-10-26	Medikamentholdigt lipidvesikelpraeparat og fremgangsmaade til fremstilling deraf
KR101391020B1 (ko)	2014-04-30	수난용성 약제를 함유한 약학 조성물
CN103110579A (zh)	2013-05-22	前列地尔注射剂
JP2000319170A (ja)	2000-11-21	テプレノン含有点眼剤
JPH047722B2 (es)	1992-02-12
FI94835B (fi)	1995-07-31	Menetelmä 2-fenyyli-1,2-bentsisoselenatsol-3(2H)-onin stabiilien parenteraalisten liuosten valmistamiseksi
US20140329774A1 (en)	2014-11-06	Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparing method thereof
CN101632634B (zh)	2010-12-15	N(2)-l-丙氨酰-l-谷氨酰胺脂质体注射剂及其制备方法
NO873626L (no)	1988-02-29	Fremgangsmaate for fremstilling av frysetoerkede farmasoeytiske preparater av fenylkinolinkarboksylsyrer.
JPH06239734A (ja)	1994-08-30	リポソームの調製法及びリポソーム製剤
JPWO2002053154A1 (ja)	2004-04-30	エマルション製剤
JPH04505018A (ja)	1992-09-03	水性混合ミセル溶液を製造する方法
AU636327B2 (en)	1993-04-29	Process for the preparation of aqueous mixed micelle solutions
NO150183B (no)	1984-05-28	Fremgangsmaate ved fremstilling av injeksjonsloesninger
JPH02289511A (ja)	1990-11-29	混合ミセル
CN108653204B (zh)	2022-04-08	一种多烯磷脂酰胆碱注射液药物组合物及其制备方法
US20220175878A1 (en)	2022-06-09	Method for preparing eye drops of cyclosporin a
JPH06256212A (ja)	1994-09-13	オーレオバシジン類のリポソーム製剤
CN101904817A (zh)	2010-12-08	一种头孢磺啶钠脂质体注射剂